Kriya Therapeutics: Gene Therapy. Redefined. Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits
Pipeline - Kriya Therapeutics Kriya is developing a portfolio of one-time gene therapies to address chronic diseases Our current pipeline includes three main therapeutic areas: Therapeutic Area
Metabolic Disease: Gene Therapy for Diabetes and NASH - Kriya Therapeutics Kriya’s KRIYA-839, an adeno-associated virus (AAV)-based gene therapy, is a groundbreaking approach to restoring insulin production and enhancing glucose metabolism in type 1 diabetes Skeletal muscle plays a key role in regulating blood glucose in response to insulin
Kriya Presents Data at the 2025 Association for Research in Vision and . . . Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy (GA) that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the objective of slowing GA lesion growth and vision loss
Kriya Announces Thirteen Presentations at the American Society of Gene . . . Kriya is a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world With operations in Research Triangle Park, North Carolina, and Palo Alto, California, Kriya has raised over $600 million to advance a broad pipeline of gene therapies in ophthalmology, metabolic disease and
Kriya Announces $150 Million Addition to its Series C, Bringing Total . . . With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease
Our Team: Leaders in Gene Therapy - Kriya Therapeutics Andrew Murphy is the Sr Vice President, Early Research at Kriya Therapeutics Dr Murphy joined Kriya from Kitty Hawk Biosciences where he developed in vitro assays to support client gene therapy programs He has over fifteen years of experience in biopharmaceutical research and development from discovery to early clinical evaluation